CCL2 and melanoma: In contrast, two other studies—one on melanoma (anti-PD-1 ± anti-CTLA-4) and one on gastrointestinal tract tumors (anti-PD-1)—reported MCP-1 as an unfavorable prognostic marker [111, 115].